Brawn Biotech Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Brawn Biotech Ltd is ₹ 20.8 as of 04 May 15:30 . The P/E Ratio of Brawn Biotech Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Brawn Biotech Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Brawn Biotech Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Brawn Biotech Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Brawn Biotech Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Brawn Biotech Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Brawn Biotech Ltd

Brawn Biotech Limited was originally incorporated in the name of Brawn Pharmaceuticals Limited in November, 1985.
Thereafter, the name of the Company was changed from Brawn Pharmaceuticals Limited to Brawn Biotech Limited in November, 2010.
Brawn, with its inception barely 38 years back has today evolved into a fully integrated, healthcare group, marking its presence in India and across the globe. The Company possess product registration with major health and govt. institutions throughout India and worldwide.
Headed and represented by a team of skilled industry experts with impressive educational backgrounds and broad experience, the Company has spread its wings in expansion in the domestic as well as in the international markets beyond the existing horizon to stand among the leading Indian HealthCare products distribution Companies.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Brawn Biotech Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Brawn Biotech Ltd or Sanofi India Ltd?

Market cap of Brawn Biotech Ltd is 5 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Brawn Biotech Ltd and Sanofi India Ltd?

The stock performance of Brawn Biotech Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Brawn Biotech Ltd and Sanofi India Ltd?

As of May 5, 2026, the Brawn Biotech Ltd stock price is INR ₹19.0. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Brawn Biotech Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Brawn Biotech Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.